Victory Capital Management Inc. Sells 13,315 Shares of Loxo Oncology Inc (LOXO)

Victory Capital Management Inc. lowered its stake in Loxo Oncology Inc (NASDAQ:LOXO) by 3.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 350,072 shares of the biopharmaceutical company’s stock after selling 13,315 shares during the period. Victory Capital Management Inc.’s holdings in Loxo Oncology were worth $59,803,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Emerald Advisers Inc. PA lifted its position in shares of Loxo Oncology by 26.8% in the third quarter. Emerald Advisers Inc. PA now owns 118,250 shares of the biopharmaceutical company’s stock worth $20,201,000 after buying an additional 25,020 shares during the last quarter. Emerald Mutual Fund Advisers Trust lifted its position in shares of Loxo Oncology by 33.8% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 109,589 shares of the biopharmaceutical company’s stock worth $18,721,000 after buying an additional 27,699 shares during the last quarter. Frontier Capital Management Co. LLC lifted its position in shares of Loxo Oncology by 93.4% in the third quarter. Frontier Capital Management Co. LLC now owns 51,542 shares of the biopharmaceutical company’s stock worth $8,805,000 after buying an additional 24,891 shares during the last quarter. Columbus Circle Investors lifted its position in shares of Loxo Oncology by 24.1% in the third quarter. Columbus Circle Investors now owns 17,781 shares of the biopharmaceutical company’s stock worth $3,038,000 after buying an additional 3,457 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado lifted its position in shares of Loxo Oncology by 85.7% in the third quarter. Public Employees Retirement Association of Colorado now owns 2,189 shares of the biopharmaceutical company’s stock worth $374,000 after buying an additional 1,010 shares during the last quarter. 97.77% of the stock is owned by institutional investors.

In related news, VP Jennifer Burstein sold 2,500 shares of the business’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $159.24, for a total transaction of $398,100.00. Following the completion of the transaction, the vice president now owns 1,250 shares of the company’s stock, valued at approximately $199,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lori Anne Kunkel sold 5,000 shares of the business’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $170.37, for a total value of $851,850.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $851,850. The disclosure for this sale can be found here. Insiders have sold a total of 102,500 shares of company stock valued at $16,798,550 in the last three months. 17.10% of the stock is owned by insiders.

NASDAQ LOXO opened at $170.85 on Wednesday. Loxo Oncology Inc has a twelve month low of $71.45 and a twelve month high of $208.95. The stock has a market cap of $5.19 billion, a P/E ratio of -32.18 and a beta of 2.26.

Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.15. The business had revenue of $42.60 million for the quarter, compared to analyst estimates of $32.36 million. During the same period in the prior year, the firm posted ($0.94) EPS. Analysts forecast that Loxo Oncology Inc will post -2.52 earnings per share for the current fiscal year.

LOXO has been the subject of a number of analyst reports. Cann reaffirmed an “average” rating and issued a $202.00 price target (up previously from $122.00) on shares of Loxo Oncology in a research report on Thursday, July 12th. Piper Jaffray Companies set a $200.00 price target on Loxo Oncology and gave the stock a “buy” rating in a research report on Wednesday, September 26th. Stifel Nicolaus reduced their price target on Loxo Oncology from $225.00 to $217.00 and set a “buy” rating for the company in a research report on Friday, August 10th. Cowen reaffirmed a “buy” rating on shares of Loxo Oncology in a research report on Thursday, August 9th. Finally, Zacks Investment Research raised Loxo Oncology from a “hold” rating to a “buy” rating and set a $189.00 price target for the company in a research report on Saturday, August 4th. One analyst has rated the stock with a sell rating, two have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $188.75.

ILLEGAL ACTIVITY WARNING: “Victory Capital Management Inc. Sells 13,315 Shares of Loxo Oncology Inc (LOXO)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/07/victory-capital-management-inc-sells-13315-shares-of-loxo-oncology-inc-loxo.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Featured Story: Inflation

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply